Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice

Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice

Up to two-thirds of patients affected by spinal cord injury (SCI) develop central neuropathic pain (CNP), which has a high impact on their quality of life. Most of the patients are largely refractory to current treatments, and new pharmacological strategies are needed. Recently, it has been shown th...

Full description

Bibliographic Details
Main Authors: Sílvia Castany, Xavier Codony, Daniel Zamanillo, Manuel Merlos, Enrique Verdú, Pere Boadas-Vaello
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Pharmacology
Subjects:
spinal cord injury
central neuropathic pain
MR309
central sensitization-related biomarkers
pro-inflammatory cytokines
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00222/full

Similar Items

Similar Items